Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 183 articles:
HTML format
Text format



Single Articles


    December 2018
  1. FUJIMOTO D, Yamashita D, Fukuoka J, Kitamura Y, et al
    Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263.
    Anticancer Res. 2018;38:6891-6895.
    PubMed     Text format     Abstract available


  2. SVATON M, Zemanova M, Skrickova J, Jakubikova L, et al
    Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:6771-6782.
    PubMed     Text format     Abstract available


    November 2018
  3. AKAIKE K, Saruwatari K, Okabayashi H, Hamada S, et al
    Negative Impact of Coexisting Interstitial Lung Disease on Clinical Outcomes in Small-cell Lung Cancer Patients.
    Anticancer Res. 2018;38:6543-6550.
    PubMed     Text format     Abstract available


  4. WU MF, Wang YC, Li HT, Chen WC, et al
    The Contribution of Interleukin-12 Genetic Variations to Taiwanese Lung Cancer.
    Anticancer Res. 2018;38:6321-6327.
    PubMed     Text format     Abstract available


  5. MOENG S, Seo HA, Hwang CY, Cipolla GA, et al
    MicroRNA-107 Targets IKBKG and Sensitizes A549 Cells to Parthenolide.
    Anticancer Res. 2018;38:6309-6316.
    PubMed     Text format     Abstract available


  6. LIU KH, Tsai YT, Chin SY, Lee WR, et al
    Hypoxia Stimulates the Epithelial-to-Mesenchymal Transition in Lung Cancer Cells Through Accumulation of Nuclear beta-Catenin.
    Anticancer Res. 2018;38:6299-6308.
    PubMed     Text format     Abstract available


  7. PHIBOONCHAIYANAN PP, Petpiroon N, Sritularak B, Chanvorachote P, et al
    Phoyunnanin E Induces Apoptosis of Non-small Cell Lung Cancer Cells via p53 Activation and Down-regulation of Survivin.
    Anticancer Res. 2018;38:6281-6290.
    PubMed     Text format     Abstract available


    October 2018
  8. WADA K, Kishi N, Kanayama N, Hirata T, et al
    Radiation Dose Escalation in Accelerated Hyperfractionated Radiotherapy for Stage III Non-small-cell Lung Cancer.
    Anticancer Res. 2018;38:5951-5958.
    PubMed     Text format     Abstract available


  9. TAKAMORI S, Takada K, Azuma K, Jogo Y, et al
    Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer.
    Anticancer Res. 2018;38:5903-5907.
    PubMed     Text format     Abstract available


  10. TAKAMORI S, Takada K, Toyokawa G, Azuma K, et al
    PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:5897-5901.
    PubMed     Text format     Abstract available


  11. CHEN GL, Shen TC, Chang WS, Tsai CW, et al
    The Contribution of MMP-7 Promoter Polymorphisms to Taiwan Lung Cancer Susceptibility.
    Anticancer Res. 2018;38:5671-5677.
    PubMed     Text format     Abstract available


  12. YOUSSEF O, Knuuttila A, Piirila P, Bohling T, et al
    Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
    Anticancer Res. 2018;38:5627-5634.
    PubMed     Text format     Abstract available


  13. THANGARAJAH F, Vogel C, Pahmeyer C, Eichler C, et al
    Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
    Anticancer Res. 2018;38:6023-6026.
    PubMed     Text format     Abstract available


  14. YOON N, Kim J, Maeng LS, Ahn JH, et al
    Prominent Nucleoli and Non-glandular Feature Are Independent Predictors of PD-L1 Expression in Lung Adenocarcinoma.
    Anticancer Res. 2018;38:6003-6008.
    PubMed     Text format     Abstract available


  15. FREEMAN J, Crowley PD, Foley AG, Gallagher HC, et al
    Effect of Perioperative Lidocaine and Cisplatin on Metastasis in a Murine Model of Breast Cancer Surgery.
    Anticancer Res. 2018;38:5599-5606.
    PubMed     Text format     Abstract available


    September 2018
  16. TAKEUCHI A, Oguri T, Yamashita Y, Sone K, et al
    TTF-1 Expression Predicts the Merit of Additional Antiangiogenic Treatment in Non-squamous Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:5489-5495.
    PubMed     Text format     Abstract available


  17. EZE C, Roengvoraphoj O, Dantes M, Abdo R, et al
    Prophylactic Cranial Irradiation for Patients with Small Cell Lung Cancer in Germany: Pattern of Care Survey.
    Anticancer Res. 2018;38:5261-5265.
    PubMed     Text format     Abstract available


  18. WU JY, Lin SS, Hsu FT, Chung JG, et al
    Fluoxetine Inhibits DNA Repair and NF-kB-modulated Metastatic Potential in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:5201-5210.
    PubMed     Text format     Abstract available


  19. HUANG YP, Jiang YW, Chen HY, Hsiao YT, et al
    Benzyl Isothiocyanate Induces Apoptotic Cell Death Through Mitochondria-dependent Pathway in Gefitinib-resistant NCI-H460 Human Lung Cancer Cells In Vitro.
    Anticancer Res. 2018;38:5165-5176.
    PubMed     Text format     Abstract available


  20. KURAMOTO K, Yamamoto M, Suzuki S, Sanomachi T, et al
    AS602801, an Anti-Cancer Stem Cell Drug Candidate, Suppresses Gap-junction Communication Between Lung Cancer Stem Cells and Astrocytes.
    Anticancer Res. 2018;38:5093-5099.
    PubMed     Text format     Abstract available


  21. LEE J, Yun HH, Kim S, Ji SH, et al
    Implication of BIS in the Migration and Invasion of A549 Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2018;38:5057-5065.
    PubMed     Text format     Abstract available


  22. HAKOZAKI M, Tamura H, Dobashi Y, Yoshida A, et al
    Establishment and Characterization of a Novel Human Clear-cell Sarcoma of Soft-tissue Cell Line, RSAR001, Derived from Pleural Effusion of a Patient with Pleural Dissemination.
    Anticancer Res. 2018;38:5035-5042.
    PubMed     Text format     Abstract available


  23. RONCHI L, Buwenge M, Cortesi A, Ammendolia I, et al
    Whole Lung Irradiation in Patients with Osteosarcoma and Ewing Sarcoma.
    Anticancer Res. 2018;38:4977-4985.
    PubMed     Text format     Abstract available


  24. MILLETT RL, Elkon JM, Tabbara IA
    Directed Therapies in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:4969-4975.
    PubMed     Text format     Abstract available


  25. MIYAZAKI K, Tamura T, Kaburagi T, Saito K, et al
    Real Clinical Practice of Using Afatinib Therapy in NSCLC Patients with an Acquired EGFR T790M Mutation.
    Anticancer Res. 2018;38:5409-5415.
    PubMed     Text format     Abstract available


  26. HEINZE C, Omari J, Othmer M, Hass P, et al
    Image-guided Interstitial Brachytherapy in the Management of Metastasized Anal Squamous Cell Carcinoma.
    Anticancer Res. 2018;38:5401-5407.
    PubMed     Text format     Abstract available


  27. TAKADA K, Toyokawa G, Tagawa T, Shimokawa M, et al
    Radiological Features of IDO1(+)/PDL1(+) Lung Adenocarcinoma: A Retrospective Single-institution Study.
    Anticancer Res. 2018;38:5295-5303.
    PubMed     Text format     Abstract available


  28. FURUTA H, Uemura T, Yoshida T, Kobara M, et al
    Efficacy and Safety Data of Osimertinib in Elderly Patients with NSCLC Who Harbor the EGFR T790M Mutation After Failure of Initial EGFR-TKI Treatment.
    Anticancer Res. 2018;38:5231-5237.
    PubMed     Text format     Abstract available


    August 2018
  29. SHIROYAMA T, Suzuki H, Tamiya M, Tamiya A, et al
    Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:4723-4729.
    PubMed     Text format     Abstract available


  30. SHIMIZU K, Okita R, Saisho S, Maeda AI, et al
    Impact of COX2 Inhibitor for Regulation of PD-L1 Expression in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:4637-4644.
    PubMed     Text format     Abstract available


  31. ONISHI H, Ichimiya S, Yanai K, Umebayashi M, et al
    RBPJ and MAML3: Potential Therapeutic Targets for Small Cell Lung Cancer.
    Anticancer Res. 2018;38:4543-4547.
    PubMed     Text format     Abstract available


  32. LEE J, Yun HH, Kim S, Ji SH, et al
    Implication of BIS in the Migration and Invasion of A549 Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2018;38:4525-4533.
    PubMed     Text format     Abstract available


  33. SPRAVE T, Verma V, Forster R, Schlampp I, et al
    Quality of Life Following Stereotactic Body Radiotherapy Versus Three-Dimensional Conformal Radiotherapy for Vertebral Metastases: Secondary Analysis of an Exploratory Phase II Randomized Trial.
    Anticancer Res. 2018;38:4961-4968.
    PubMed     Text format     Abstract available


  34. WATANABE S, Yamaguchi OU, Masumoto AI, Maeno Y, et al
    Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs.
    Anticancer Res. 2018;38:4699-4704.
    PubMed     Text format     Abstract available


    July 2018
  35. BAXA J, Matouskova T, Ludvik J, Sedlmair M, et al
    Single-source Dual-energy CT as a Part of (18)F-FDG PET/CT: Direct Comparison of Iodine-related and Metabolic Parameters in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:4131-4137.
    PubMed     Text format     Abstract available


  36. SCHMID S, Csanadi A, Kozhuharov N, Tchudjin M, et al
    CC-Chemokine Ligand 18 Is an Independent Prognostic Marker in Lymph Node-positive Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:3913-3918.
    PubMed     Text format     Abstract available


  37. MAIUTHED A, Chantarawong W, Chanvorachote P
    Lung Cancer Stem Cells and Cancer Stem Cell-targeting Natural Compounds.
    Anticancer Res. 2018;38:3797-3809.
    PubMed     Text format     Abstract available


  38. ARIMOTO A, Yamashita K, Hasegawa H, Sugita Y, et al
    Immunosuppression Induced by Perioperative Peritonitis Promotes Lung Metastasis.
    Anticancer Res. 2018;38:4333-4338.
    PubMed     Text format     Abstract available


  39. TUPY R, Mirka H, Mracek J, Priban V, et al
    Tumor-related Perfusion Changes in White Matter Adjacent to Brain Tumors: Pharmacodynamic Analysis of Dynamic 3T Magnetic Resonance Imaging.
    Anticancer Res. 2018;38:4149-4152.
    PubMed     Text format     Abstract available


  40. USUDA K, Iwai S, Funasaki A, Sekimura A, et al
    Expression and Prognostic Impact of VEGF, CD31 and alphaSMA in Resected Primary Lung Cancers.
    Anticancer Res. 2018;38:4057-4063.
    PubMed     Text format     Abstract available


  41. BASSANELLI M, Sioletic S, Martini M, Giacinti S, et al
    Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC.
    Anticancer Res. 2018;38:3789-3796.
    PubMed     Text format     Abstract available


    June 2018
  42. TAKEOKA H, Yamada K, Naito Y, Matsuo N, et al
    Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab with Maintenance Bevacizumab as a First-line Treatment for Advanced Non-squamous Non-small Cell Lung Cancer in Elderly Patients.
    Anticancer Res. 2018;38:3779-3784.
    PubMed     Text format     Abstract available


  43. SHOJI F, Yamazaki K, Miura N, Katsura M, et al
    Postoperative Management of Multiple Primary Cancers Associated with Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:3773-3778.
    PubMed     Text format     Abstract available


  44. SYRIGOS KN, Georgoulias V, Zarogoulidis K, Makrantonakis P, et al
    Epidemiological Characteristics, EGFR Status and Management Patterns of Advanced Non-small Cell Lung Cancer Patients: The Greek REASON Observational Registry Study.
    Anticancer Res. 2018;38:3735-3744.
    PubMed     Text format     Abstract available


  45. TAKAMORI S, Toyokawa G, Shimokawa M, Kinoshita F, et al
    Radiological Features of Brain Metastases from Non-small Cell Lung Cancer Harboring EGFR Mutation.
    Anticancer Res. 2018;38:3731-3734.
    PubMed     Text format     Abstract available


  46. TOYOKAWA G, Takada K, Tagawa T, Kinoshita F, et al
    Prevalence of Enhancer of Zeste Homolog 2 in Patients with Resected Small Cell Lung Cancer.
    Anticancer Res. 2018;38:3707-3711.
    PubMed     Text format     Abstract available


  47. BANNA GL, Camerini A, Bronte G, Anile G, et al
    Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy.
    Anticancer Res. 2018;38:3689-3697.
    PubMed     Text format     Abstract available


  48. MATSUMOTO T, Hasebe T, Baba Y, Chosa K, et al
    Feasibility and Safety of CT-guided Intrathoracic and Bone Re-biopsy for Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:3587-3592.
    PubMed     Text format     Abstract available


  49. RAUNGRUT P, Wongkotsila A, Champoochana N, Lirdprapamongkol K, et al
    Knockdown of 14-3-3gamma Suppresses Epithelial-Mesenchymal Transition and Reduces Metastatic Potential of Human Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2018;38:3507-3514.
    PubMed     Text format     Abstract available


  50. KOYI H, Branden E, Kasim I, Wilander E, et al
    Co-localisation of Glandular and Squamous Cell Markers in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:3341-3346.
    PubMed     Text format     Abstract available


  51. LAI JZ, Lai HH, Cao D
    Renal Cell Carcinoma, Unclassified with Medullary Phenotype and Synchronous Renal Clear Cell Carcinoma Present in a Patient with No Sickle Cell Trait/Disease: Diagnostic and Therapeutic Challenges.
    Anticancer Res. 2018;38:3757-3761.
    PubMed     Text format     Abstract available


  52. HAGI T, Nakamura T, Sugino Y, Matsubara T, et al
    Is FDG-PET/CT Useful for Diagnosing Pulmonary Metastasis in Patients with Soft Tissue Sarcoma?
    Anticancer Res. 2018;38:3635-3639.
    PubMed     Text format     Abstract available


  53. MASUHIRO K, Shiroyama T, Suzuki H, Takata SO, et al
    Impact of Pleural Effusion on Outcomes of Patients Receiving Osimertinib for NSCLC Harboring EGFR T790M.
    Anticancer Res. 2018;38:3567-3571.
    PubMed     Text format     Abstract available


  54. KOMIYA K, Nakashima C, Nakamura T, Hirakawa H, et al
    Current Status and Problems of T790M Detection, a Molecular Biomarker of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors, with Liquid Biopsy and Re-biopsy.
    Anticancer Res. 2018;38:3559-3566.
    PubMed     Text format     Abstract available


  55. LIN MX, Lin SH, Lin CC, Yang CC, et al
    In Vitro and In Vivo Antitumor Effects of Pyrimethamine on Non-small Cell Lung Cancers.
    Anticancer Res. 2018;38:3435-3445.
    PubMed     Text format     Abstract available


  56. ASANO M, Matsui J, Towle MJ, Wu J, et al
    Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven(R)): Combination with Anticancer Agents of Differing Mechanisms.
    Anticancer Res. 2018;38:3375-3385.
    PubMed     Text format     Abstract available


    May 2018
  57. SHINOHARA S, Sugaya M, Onitsuka T, Machida K, et al
    Prognostic Impact of Postoperative C-reactive Protein for Non-small Cell Lung Cancer Following Lobectomy.
    Anticancer Res. 2018;38:3193-3198.
    PubMed     Text format     Abstract available


  58. KINOSHITA F, Toyokawa G, Tagawa T, Matsubara T, et al
    Takotsubo Cardiomyopathy Developed After Two-stage Surgery for Double Primary Lung Cancer.
    Anticancer Res. 2018;38:2957-2960.
    PubMed     Text format     Abstract available


  59. ALMQUIST D, Khanal N, Smith L, Ganti AK, et al
    Preoperative Pulmonary Function Tests (PFTs) and Outcomes from Resected Early Stage Non-small Cell Lung Cancer (NSCLC).
    Anticancer Res. 2018;38:2903-2907.
    PubMed     Text format     Abstract available


  60. LIAO TY, Liaw CC, Tsui KH, Juan YH, et al
    Renal Pelvis Carcinoma with Renal Vein or Inferior Vena Cava Involvement Linked to Early-onset Lung Metastasis Based on CT Scan Diagnosis.
    Anticancer Res. 2018;38:3187-3192.
    PubMed     Text format     Abstract available


  61. KABURAGI T, Kiyoshima M, Nawa T, Ichimura H, et al
    Acquired EGFR T790M Mutation After Relapse Following EGFR-TKI Therapy: A Population-based Multi-institutional Study.
    Anticancer Res. 2018;38:3145-3150.
    PubMed     Text format     Abstract available


  62. KAWAGUCHI Y, Okano T, Kakihana M, Kajiwara N, et al
    Transition Rate from EGFR-TKI to Cytotoxic Chemotherapy Patients with EGFR Mutation-positive Lung Adenocarcinoma.
    Anticancer Res. 2018;38:3127-3132.
    PubMed     Text format     Abstract available


  63. TANAKA K, Toyokawa G, Tagawa T, Ijichi K, et al
    Successful Treatment of Growing Teratoma Syndrome of the Lung by Surgical Resection: A Case Report and Literature Review.
    Anticancer Res. 2018;38:3115-3118.
    PubMed     Text format     Abstract available


  64. OHNO T, Kubouchi Y, Wakahara M, Nosaka K, et al
    Clinical Significance of Subcellular Localization of Maspin in Patients with Pathological Stage IA Lung Adenocarcinoma.
    Anticancer Res. 2018;38:3001-3007.
    PubMed     Text format     Abstract available


    April 2018
  65. TAKEMURA Y, Chihara Y, Morimoto Y, Tanimura K, et al
    Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:2385-2390.
    PubMed     Text format     Abstract available


  66. LUND-IVERSEN M, Scott H, Strom EH, Theiss N, et al
    Expression of Estrogen Receptor-alpha and Survival in Advanced-stage Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:2261-2269.
    PubMed     Text format     Abstract available


  67. VO VTA, Choi JW, Phan ANH, Hua TNM, et al
    TRAP1 Inhibition Increases Glutamine Synthetase Activity in Glutamine Auxotrophic Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2018;38:2187-2193.
    PubMed     Text format     Abstract available


  68. CHEN WT, Chen YK, Lin SS, Hsu FT, et al
    Hyperforin Suppresses Tumor Growth and NF-kappaB-mediated Anti-apoptotic and Invasive Potential of Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:2161-2167.
    PubMed     Text format     Abstract available


  69. BIANCONI F, Fravolini ML, Bello-Cerezo R, Minestrini M, et al
    Evaluation of Shape and Textural Features from CT as Prognostic Biomarkers in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:2155-2160.
    PubMed     Text format     Abstract available


  70. HSIA TC, Huang YP, Jiang YW, Chen HY, et al
    Phenethyl Isothiocyanate Induces Apoptotic Cell Death Through the Mitochondria-dependent Pathway in Gefitinib-resistant NCI-H460 Human Lung Cancer Cells In Vitro.
    Anticancer Res. 2018;38:2137-2147.
    PubMed     Text format     Abstract available


  71. KANAJI N, Yokohira M, Watanabe N, Kadowaki N, et al
    Transforming Growth Factor-Beta Produced by Non-small Cell Lung Cancer Cells Contributes to Lung Fibroblast Contractile Phenotype.
    Anticancer Res. 2018;38:2007-2014.
    PubMed     Text format     Abstract available


  72. MATSUMOTO N, Kumasaka A, Ando T, Komiyama K, et al
    Detection of EGFR Gene Mutation by Mutation-oriented LAMP Method.
    Anticancer Res. 2018;38:2093-2099.
    PubMed     Text format     Abstract available


  73. RZECHONEK A, Grzegrzolka J, Blasiak P, Ornat M, et al
    Correlation of Expression of Tenascin C and Blood Vessel Density in Non-small Cell Lung Cancers.
    Anticancer Res. 2018;38:1987-1991.
    PubMed     Text format     Abstract available


  74. SATAKE T, Suetsugu A, Nakamura M, Hasegawa K, et al
    Differential Organ-targeting and Cellular Characteristics of Metastatic Human Pancreatic Cancer Cell Lines in Mouse Models.
    Anticancer Res. 2018;38:1927-1935.
    PubMed     Text format     Abstract available


    March 2018
  75. TOYOKAWA G, Yamada Y, Tagawa T, Kinoshita F, et al
    High Frequency of Spread Through Air Spaces in Resected Small Cell Lung Cancer.
    Anticancer Res. 2018;38:1821-1825.
    PubMed     Text format     Abstract available


  76. NASU S, Suzuki H, Shiroyama T, Tanaka A, et al
    Skin Rash Can Be a Useful Marker for Afatinib Efficacy.
    Anticancer Res. 2018;38:1783-1788.
    PubMed     Text format     Abstract available


  77. MATSUBARA T, Toyokawa G, Kinoshita F, Haratake N, et al
    Safety of Simultaneous Bilateral Pulmonary Resection for Metastatic Lung Tumors.
    Anticancer Res. 2018;38:1715-1719.
    PubMed     Text format     Abstract available


  78. SATO Y, Fujimoto D, Uehara K, Kawachi H, et al
    Reduced Tumour Proportion Scores for Programmed Cell Death Ligand 1 in Stored Paraffin Tissue Sections.
    Anticancer Res. 2018;38:1401-1405.
    PubMed     Text format     Abstract available


    February 2018
  79. KATO Y, Kashima J, Watanabe K, Yomota M, et al
    Association Between Clinicopathological Features and Programmed Death Ligand 1 Expression in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:1077-1083.
    PubMed     Text format     Abstract available


  80. HORTON CE, Kamal M, Leslie M, Zhang R, et al
    Circulating Tumor Cells Accurately Predicting Progressive Disease After Treatment in a Patient with Non-small Cell Lung Cancer Showing Response on Scans.
    Anticancer Res. 2018;38:1073-1076.
    PubMed     Text format     Abstract available


  81. SAITOH JI, Shirai K, Abe T, Kubo N, et al
    A Phase I Study of Hypofractionated Carbon-ion Radiotherapy for Stage III Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:885-891.
    PubMed     Text format     Abstract available


  82. VALAN CD, Slagsvold JE, Halvorsen TO, Herje M, et al
    Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement.
    Anticancer Res. 2018;38:871-876.
    PubMed     Text format     Abstract available


  83. GLATZEL-PLUCINSKA N, Piotrowska A, Grzegrzolka J, Olbromski M, et al
    SATB1 Level Correlates with Ki-67 Expression and Is a Positive Prognostic Factor in Non-small Cell Lung Carcinoma.
    Anticancer Res. 2018;38:723-736.
    PubMed     Text format     Abstract available


  84. KOH YW, Park SY, Hyun SH, Lee SJ, et al
    Associations Between PET Textural Features and GLUT1 Expression, and the Prognostic Significance of Textural Features in Lung Adenocarcinoma.
    Anticancer Res. 2018;38:1067-1071.
    PubMed     Text format     Abstract available


  85. HIRAI F, Kinoshita I, Matsubara T, Haratake N, et al
    Which Primary Organ Is Most Suitable for Performing Pulmonary Metastasectomy?
    Anticancer Res. 2018;38:1041-1045.
    PubMed     Text format     Abstract available


  86. ROBELLA M, Vaira M, Borsano A, Mossetti C, et al
    Low-dose Pressurized Intrathoracic Aerosol Chemotherapy (PITAC) as an Alternative Therapy for Pleuropulmonary Involvement in Pseudomyxoma Peritonei.
    Anticancer Res. 2018;38:929-932.
    PubMed     Text format     Abstract available


  87. KOBAYASHI K, Seike M, Zou F, Noro R, et al
    Prognostic Significance of NSCLC and Response to EGFR-TKIs of EGFR-Mutated NSCLC Based on PD-L1 Expression.
    Anticancer Res. 2018;38:753-762.
    PubMed     Text format     Abstract available


  88. AKIMOTO J, Nakayama M, Takagi S, Okano T, et al
    Improved In Vivo Subcutaneous Tumor Generation by Cancer Cell Sheet Transplantation.
    Anticancer Res. 2018;38:671-676.
    PubMed     Text format     Abstract available


  89. NIEDER C, Kampe TA, Engljahringer K
    Does Patient-reported Dyspnea Reflect Thoracic Disease Characteristics in Patients with Incurable Cancer?
    Anticancer Res. 2018;38:901-904.
    PubMed     Text format     Abstract available


    January 2018
  90. KATAOKA Y, Hirano K, Narabayashi T, Hara S, et al
    Carcinoembryonic Antigen as a Predictive Biomarker of Response to Nivolumab in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:559-563.
    PubMed     Text format     Abstract available


  91. TAKAMORI S, Toyokawa G, Okamoto I, Takada K, et al
    Clinical Significance of PD-L1 Expression in Brain Metastases from Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:553-557.
    PubMed     Text format     Abstract available


  92. SLUGA R, VAN DEN Borne BEEM, Roepman P, Peters BJM, et al
    Utilization of Molecular Testing and Survival Outcomes of Treatment with First- or Second-line Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer in a Dutch Population.
    Anticancer Res. 2018;38:393-400.
    PubMed     Text format     Abstract available


  93. JUNG CY, Kim SY, Lee C
    Carvacrol Targets AXL to Inhibit Cell Proliferation and Migration in Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2018;38:279-286.
    PubMed     Text format     Abstract available


  94. SHEN TC, Chang WS, Tsai CW, Chao CY, et al
    The Contribution of Matrix Metalloproteinase-1 Promoter Genotypes in Taiwan Lung Cancer Risk.
    Anticancer Res. 2018;38:253-257.
    PubMed     Text format     Abstract available


  95. FANG T, Huang H, Li X, Liao J, et al
    Effects of siRNA Silencing of TUG1 and LCAL6 Long Non-coding RNAs on Patient-derived Xenograft of Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:179-186.
    PubMed     Text format     Abstract available


  96. DAMASKOS C, Tomos I, Garmpis N, Karakatsani A, et al
    Histone Deacetylase Inhibitors as a Novel Targeted Therapy Against Non-small Cell Lung Cancer: Where Are We Now and What Should We Expect?
    Anticancer Res. 2018;38:37-43.
    PubMed     Text format     Abstract available


  97. PRECIVAL C, Landy M, Poole C, Mullaney L, et al
    The Role of Prophylactic Cranial Irradiation for Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:7-14.
    PubMed     Text format     Abstract available


  98. HIGUCHI T, Yamamoto N, Hayashi K, Takeuchi A, et al
    The Efficacy of Wide Resection for Musculoskeletal Metastatic Lesions of Renal Cell Carcinoma.
    Anticancer Res. 2018;38:577-582.
    PubMed     Text format     Abstract available


    December 2017
  99. TAKADA K, Toyokawa G, Tagawa T, Kohashi K, et al
    Association Between PD-L1 Expression and Metabolic Activity on (18)F-FDG PET/CT in Patients with Small-sized Lung Cancer.
    Anticancer Res. 2017;37:7073-7082.
    PubMed     Text format     Abstract available


  100. SHOJI F, Matsubara T, Kozuma Y, Haratake N, et al
    Relationship Between Preoperative Sarcopenia Status and Immuno-nutritional Parameters in Patients with Early-stage Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:6997-7003.
    PubMed     Text format     Abstract available


  101. KULDA V, Hrda K, Houdek Z, Dobra JK, et al
    Predictive Significance of Thymidylate Synthase Expression in Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:6953-6958.
    PubMed     Text format     Abstract available


  102. ERBER R, Stohr R, Herlein S, Giedl C, et al
    Comparison of PD-L1 mRNA Expression Measured with the CheckPoint Typer(R) Assay with PD-L1 Protein Expression Assessed with Immunohistochemistry in Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:6771-6778.
    PubMed     Text format     Abstract available


  103. MATSUBARA T, Toyokawa G, Yamada Y, Nabeshima K, et al
    A Case of the Resected Lymphohistiocytoid Mesothelioma: BAP1 Is a Key of Accurate Diagnosis.
    Anticancer Res. 2017;37:6937-6941.
    PubMed     Text format     Abstract available


    November 2017
  104. OYA Y, Yoshida T, Kuroda H, Shimizu J, et al
    Clinical Efficacy of Alectinib in Patients with ALK-Rearranged Non-small Cell Lung Cancer After Ceritinib Failure.
    Anticancer Res. 2017;37:6477-6480.
    PubMed     Text format     Abstract available


  105. WILLS B, Cardona AF, Rojas L, Ruiz-Patino A, et al
    Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab.
    Anticancer Res. 2017;37:6429-6436.
    PubMed     Text format     Abstract available


  106. TUNGSUKRUTHAI S, Sritularak B, Chanvorachote P
    Cycloartobiloxanthone Inhibits Migration and Invasion of Lung Cancer Cells.
    Anticancer Res. 2017;37:6311-6319.
    PubMed     Text format     Abstract available


  107. PINKHIEN T, Petpiroon N, Sritularak B, Chanvorachote P, et al
    Batatasin III Inhibits Migration of Human Lung Cancer Cells by Suppressing Epithelial to Mesenchymal Transition and FAK-AKT Signals.
    Anticancer Res. 2017;37:6281-6289.
    PubMed     Text format     Abstract available


  108. MAIUTHED A, Pinkhien T, Chamni S, Suwanborirux K, et al
    Apoptosis-inducing Effect of Hydroquinone 5-O-Cinnamoyl Ester Analog of Renieramycin M on Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2017;37:6259-6267.
    PubMed     Text format     Abstract available


  109. ICHIHARA H, Kuwabara K, Matsumoto Y
    Trehalose Liposomes Suppress the Growth of Tumors on Human Lung Carcinoma-bearing Mice by Induction of Apoptosis In Vivo.
    Anticancer Res. 2017;37:6133-6139.
    PubMed     Text format     Abstract available


  110. MORIN C, Fortin S
    Docosahexaenoic Acid Monoglyceride Increases Carboplatin Activity in Lung Cancer Models by Targeting EGFR.
    Anticancer Res. 2017;37:6015-6023.
    PubMed     Text format     Abstract available


  111. FIALA O, Hosek P, Pesek M, Finek J, et al
    Serum Concentration of Erlotinib and its Correlation with Outcome and Toxicity in Patients with Advanced-stage NSCLC.
    Anticancer Res. 2017;37:6469-6476.
    PubMed     Text format     Abstract available


  112. MULLER L, Radtke A, Decker J, Koch M, et al
    The Synthetic Cannabinoid WIN 55,212-2 Elicits Death in Human Cancer Cell Lines.
    Anticancer Res. 2017;37:6341-6345.
    PubMed     Text format     Abstract available


  113. SANOMACHI T, Suzuki S, Kuramoto K, Takeda H, et al
    Olanzapine, an Atypical Antipsychotic, Inhibits Survivin Expression and Sensitizes Cancer Cells to Chemotherapeutic Agents.
    Anticancer Res. 2017;37:6177-6188.
    PubMed     Text format     Abstract available


    October 2017
  114. SHOJI F, Yamashita N, Inoue Y, Kozuma Y, et al
    Surgical Resection and Outcome of Synchronous and Metachronous Primary Lung Cancer in Breast Cancer Patients.
    Anticancer Res. 2017;37:5871-5876.
    PubMed     Text format     Abstract available


  115. TANIGUCHI Y, Tamiya A, Isa SI, Nakahama K, et al
    Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab.
    Anticancer Res. 2017;37:5857-5862.
    PubMed     Text format     Abstract available


  116. MATSUMOTO Y, Ohara S, Furukawa R, Usui K, et al
    The Prognosis of Small Cell Lung Cancer in Patients with Pulmonary Fibrosis.
    Anticancer Res. 2017;37:5791-5795.
    PubMed     Text format     Abstract available


  117. TAKEUCHI A, Oguri T, Sone K, Ito K, et al
    Predictive and Prognostic Value of CYFRA 21-1 for Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs.
    Anticancer Res. 2017;37:5771-5776.
    PubMed     Text format     Abstract available


  118. SHIBA S, Saitoh JI, Irie D, Shirai K, et al
    Potential Pitfalls of a Fiducial Marker-matching Technique in Carbon-ion Radiotherapy for Lung Cancer.
    Anticancer Res. 2017;37:5673-5680.
    PubMed     Text format     Abstract available


  119. SUDO K, Sato K, Sakamoto S, Hasegawa Y, et al
    Association Between Endothelial Progenitor Cells and Treatment Response in Non-Squamous Non-small Cell Lung Cancer Treated with Bevacizumab.
    Anticancer Res. 2017;37:5565-5571.
    PubMed     Text format     Abstract available


  120. NAKAHAMA K, Isa SI, Tamiya A, Taniguchi Y, et al
    The Association Between Chemotherapy Immediately Before Nivolumab and Outcomes Thereafter.
    Anticancer Res. 2017;37:5885-5891.
    PubMed     Text format     Abstract available


  121. HARATAKE N, Toyokawa G, Tagawa T, Kozuma Y, et al
    Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab.
    Anticancer Res. 2017;37:5713-5717.
    PubMed     Text format     Abstract available


  122. YASUKAWA M, Kawaguchi T, Kawai N, Tojo T, et al
    Surgical Treatment for Pulmonary Metastasis of Pancreatic Ductal Adenocarcinoma: Study of 12 Cases.
    Anticancer Res. 2017;37:5573-5576.
    PubMed     Text format     Abstract available


    September 2017
  123. CELIK E, Semrau R, Baues C, Trommer-Nestler M, et al
    Robot-assisted Extracranial Stereotactic Radiotherapy of Adrenal Metastases in Oligometastatic Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:5285-5291.
    PubMed     Text format     Abstract available


  124. TAMIYA A, Tamiya M, Nakahama K, Taniguchi Y, et al
    Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:5199-5205.
    PubMed     Text format     Abstract available


  125. SHINTANI T, Matsuo Y, Iizuka Y, Mitsuyoshi T, et al
    Prognostic Significance of Serum CEA for Non-small Cell Lung Cancer Patients Receiving Stereotactic Body Radiotherapy.
    Anticancer Res. 2017;37:5161-5167.
    PubMed     Text format     Abstract available


  126. SONE K, Oguri T, Ito K, Kitamura Y, et al
    Predictive Role of CYFRA21-1 and CEA for Subsequent Docetaxel in Non-small Cell Lung Cancer Patients.
    Anticancer Res. 2017;37:5125-5131.
    PubMed     Text format     Abstract available


  127. ONISHI H, Nakamura K, Nagai S, Yanai K, et al
    Hedgehog Inhibition Upregulates TRK Expression to Antagonize Tumor Suppression in Small Cell Lung Cancer Cells.
    Anticancer Res. 2017;37:4987-4992.
    PubMed     Text format     Abstract available


  128. HAMAGUCHI R, Okamoto T, Sato M, Hasegawa M, et al
    Effects of an Alkaline Diet on EGFR-TKI Therapy in EGFR Mutation-positive NSCLC.
    Anticancer Res. 2017;37:5141-5145.
    PubMed     Text format     Abstract available


  129. ANNEDE P, Darreon J, Benkemouche A, Valdenaire S, et al
    Flattening Filter Free vs. Flattened Beams for Lung Stereotactic Body Radiation Therapy.
    Anticancer Res. 2017;37:5133-5139.
    PubMed     Text format     Abstract available


  130. AMPIL F, Ellika S, Nanda A, Vora M, et al
    Long-term Survival After Stereotactic Radiosurgery of Brain Metastases: A Case Series with 10-year Follow-up.
    Anticancer Res. 2017;37:5113-5115.
    PubMed     Text format     Abstract available


  131. DIVELLA R, Daniele A, DE Luca R, Simone M, et al
    Circulating Levels of VEGF and CXCL1 Are Predictive of Metastatic Organotropismin in Patients with Colorectal Cancer.
    Anticancer Res. 2017;37:4867-4871.
    PubMed     Text format     Abstract available


  132. TAKENAKA T, Katayama M, Sugiyama A, Hagiwara M, et al
    Gefitinib Enhances Mitochondrial Biological Functions in NSCLCs with EGFR Mutations at a High Cell Density.
    Anticancer Res. 2017;37:4779-4788.
    PubMed     Text format     Abstract available


    August 2017
  133. HE Q, Bi X, Ren C, Wang Y, et al
    Phase II Study of the Efficacy and Safety of High-dose Pemetrexed in Combination with Cisplatin Versus Temozolomide for the Treatment of Non-small Cell Lung Cancer with Brain Metastases.
    Anticancer Res. 2017;37:4711-4716.
    PubMed     Text format     Abstract available


  134. WONG W, Sun P, Mu Z, Liu J, et al
    Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:4687-4691.
    PubMed     Text format     Abstract available


  135. YANG Y, Sun N, Sun P, Zhang L, et al
    Clinical Characteristics and Prognosis of Elderly Small Cell Lung Cancer Patients Complicated with Hyponatremia: A Retrospective Analysis.
    Anticancer Res. 2017;37:4681-4686.
    PubMed     Text format     Abstract available


  136. WANG F, Lu J, Li S, Huo X, et al
    Application of Serum ELAVL4 (HuD) Antigen Assay for Small Cell Lung Cancer Diagnosis.
    Anticancer Res. 2017;37:4515-4522.
    PubMed     Text format     Abstract available


  137. YANG F, Gu Y, Zhao Z, Huang J, et al
    NHERF1 Suppresses Lung Cancer Cell Migration by Regulation of Epithelial-Mesenchymal Transition.
    Anticancer Res. 2017;37:4405-4414.
    PubMed     Text format     Abstract available


  138. ZHAO Z, Cheng S, Zabkiewicz C, Chen J, et al
    Reduced Expression of RanBPM Is Associated with Poorer Survival from Lung Cancer and Increased Proliferation and Invasion of Lung Cancer Cells In Vitro.
    Anticancer Res. 2017;37:4389-4397.
    PubMed     Text format     Abstract available


  139. FLAMINI V, Jiang WG, Cui Y
    Therapeutic Role of MiR-140-5p for the Treatment of Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:4319-4327.
    PubMed     Text format     Abstract available


  140. YU Z, Sanders AJ, Owen S, Cheng S, et al
    Expression of Osteoprotegrin Is Enhanced in Lung Cancer Tissues and Promotes Aggressive Cellular Traits in H3122 Lung Cancer Cells.
    Anticancer Res. 2017;37:4277-4283.
    PubMed     Text format     Abstract available


  141. TAKAMORI S, Toyokawa G, Okamoto I, Takada K, et al
    Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:4223-4228.
    PubMed     Text format     Abstract available


  142. TAMIYA A, Tamiya M, Nishihara T, Shiroyama T, et al
    Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study.
    Anticancer Res. 2017;37:4177-4182.
    PubMed     Text format     Abstract available


  143. ARIYASU R, Horiike A, Yoshizawa T, Dotsu Y, et al
    Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy.
    Anticancer Res. 2017;37:4229-4232.
    PubMed     Text format     Abstract available


    July 2017
  144. YOTSUMOTO F, Fukagawa S, Miyata K, Nam SO, et al
    HB-EGF Is a Promising Therapeutic Target for Lung Cancer with Secondary Mutation of EGFRT790M.
    Anticancer Res. 2017;37:3825-3831.
    PubMed     Text format     Abstract available


  145. NAKAO M, Muramatsu H, Kagawa Y, Suzuki Y, et al
    Immunological Status May Predict Response to Nivolumab in Non-small Cell Lung Cancer without Driver Mutations.
    Anticancer Res. 2017;37:3781-3786.
    PubMed     Text format     Abstract available


  146. BANNA GL, Parra HJS, Castaing M, Dieci MV, et al
    Histology-based Combination Induction Chemotherapy for Elderly Patients with Clinical Stage III Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:3723-3728.
    PubMed     Text format     Abstract available


  147. SHEN TC, Hsia TC, Chao CY, Chen WC, et al
    The Contribution of MMP-8 Promoter Polymorphisms in Lung Cancer.
    Anticancer Res. 2017;37:3563-3567.
    PubMed     Text format     Abstract available


  148. PANCEWICZ-WOJTKIEWICZ J, Bernatowicz PL
    The Effect of Afatinib Treatment in Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2017;37:3543-3546.
    PubMed     Text format     Abstract available


  149. OTSUKA T, Nojiri T, Minami S, Hosoda H, et al
    Evaluation of Natriuretic Peptide in Non-small Cell Lung Cancer Patients Treated with Bevacizumab Together with Carboplatin-Paclitaxel: A Prospective Study.
    Anticancer Res. 2017;37:3505-3512.
    PubMed     Text format     Abstract available


  150. KOBAYASHI H, Hamasaki M, Morishita T, Inoue T, et al
    Analysis of Evolving Clinicopathological Features of Metastatic Brain Tumors Over 30 Years of Surgical Management.
    Anticancer Res. 2017;37:3969-3974.
    PubMed     Text format     Abstract available


  151. MARIAMPILLAI AI, Cruz JPD, Suh J, Sivapiragasam A, et al
    Cancer Antigen 72-4 for the Monitoring of Advanced Tumors of the Gastrointestinal Tract, Lung, Breast and Ovaries.
    Anticancer Res. 2017;37:3649-3656.
    PubMed     Text format     Abstract available


    June 2017
  152. TAGAWA T, Ito K, Fukuzawa K, Okamoto T, et al
    Surgical Outcomes of Non-small Cell Lung Cancer in Patients with a History of Pancreaticobiliary Cancer.
    Anticancer Res. 2017;37:3307-3309.
    PubMed     Text format     Abstract available


  153. NAKAMICHI S, Seike M, Miyanaga A, Chiba M, et al
    RT-PCR for Detecting ALK Translocations in Cytology Samples from Lung Cancer Patients.
    Anticancer Res. 2017;37:3295-3299.
    PubMed     Text format     Abstract available


  154. MUTO S, Takagi H, Owada Y, Inoue T, et al
    Serum Nitric Oxide as a Predictive Biomarker for Bevacizumab in Non-small Cell Lung Cancer Patients.
    Anticancer Res. 2017;37:3169-3174.
    PubMed     Text format     Abstract available


  155. WANG W, Zhong W, Chen C, Meng Q, et al
    Circulating Antibodies to Linear Peptide Antigens Derived from ANXA1 and FOXP3 in Lung Cancer.
    Anticancer Res. 2017;37:3151-3155.
    PubMed     Text format     Abstract available


  156. SINAGRA E, Raimondo D, Gallo E, Stella M, et al
    JC Virus and Lung Adenocarcinoma: Fact or Myth?
    Anticancer Res. 2017;37:3311-3314.
    PubMed     Text format     Abstract available


  157. KADERBHAI C, Richard C, Fumet JD, Aarnink A, et al
    Antibiotic Use Does Not Appear to Influence Response to Nivolumab.
    Anticancer Res. 2017;37:3195-3200.
    PubMed     Text format     Abstract available


  158. MENCOBONI M, Filiberti RA, Taveggia P, Del Corso L, et al
    Safety of First-line Chemotherapy with Metronomic Single-agent Oral Vinorelbine in Elderly Patients with NSCLC.
    Anticancer Res. 2017;37:3189-3194.
    PubMed     Text format     Abstract available


  159. RIZZARDI C, Athanasakis E, Cammisuli F, Monego SD, et al
    Puzzling Results from BAP1 Germline Mutations Analysis in a Group of Asbestos-Exposed Patients in a High-risk Area of Northeast Italy.
    Anticancer Res. 2017;37:3073-3083.
    PubMed     Text format     Abstract available


    May 2017
  160. YOSHIDA H, Kim YH, Ozasa H, Nagai H, et al
    EGFR T790M Detection in Circulating Tumor DNA from Non-small Cell Lung Cancer Patients Using the PNA-LNA Clamp Method.
    Anticancer Res. 2017;37:2721-2725.
    PubMed     Text format     Abstract available


  161. SHOJI F, Toyokawa G, Harada N, Itoh S, et al
    Surgical Treatment and Outcome of Patients with De Novo Lung Cancer After Liver Transplantation.
    Anticancer Res. 2017;37:2619-2623.
    PubMed     Text format     Abstract available


  162. JANSSEN S, VAN Oorschot B, Kasmann L, Schild SE, et al
    Validation of a Score Developed to Estimate the 6-month Survival of Patients Treated with Palliative Local Radiotherapy for Advanced Lung Cancer.
    Anticancer Res. 2017;37:2537-2540.
    PubMed     Text format     Abstract available


  163. LIU D, Nakashima N, Nakano J, Tarumi S, et al
    Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
    Anticancer Res. 2017;37:2501-2507.
    PubMed     Text format     Abstract available


  164. DE MARINIS F, Bidoli P, Luciani A, Amoroso D, et al
    EAGLES study: First-line Bevacizumab in Combination with Chemotherapy in Elderly Patients with Advanced, Metastatic, Non-squamous Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:2457-2464.
    PubMed     Text format     Abstract available


  165. CHUANG CL, Wang CH, Hsu CH, Hsiao CL, et al
    Contribution of Double-strand Break Repair Gene Nijmegen Breakage Syndrome 1 Genotypes, Gender Difference and Smoking Status to Taiwanese Lung Cancer.
    Anticancer Res. 2017;37:2417-2423.
    PubMed     Text format     Abstract available


  166. LEE AY, Kim S, Lee S, Jiang HL, et al
    Knockdown of Importin 7 Inhibits Lung Tumorigenesis in K-rasLA1 Lung Cancer Mice.
    Anticancer Res. 2017;37:2381-2386.
    PubMed     Text format     Abstract available


  167. MASAGO K, Fujita S, Hata A, Okuda C, et al
    PD-L1 Expression in Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:2269-2274.
    PubMed     Text format     Abstract available


  168. HAO C, Cui Y, Hu MU, Zhi X, et al
    OPN-a Splicing Variant Expression in Non-small Cell Lung Cancer and its Effects on the Bone Metastatic Abilities of Lung Cancer Cells In Vitro.
    Anticancer Res. 2017;37:2245-2254.
    PubMed     Text format     Abstract available


  169. TOKUNAGA S, Nagano T, Kobayashi K, Katsurada M, et al
    Amphiregulin as a Novel Resistance Factor for Amrubicin in Lung Cancer Cells.
    Anticancer Res. 2017;37:2225-2231.
    PubMed     Text format     Abstract available


  170. AKAMINE T, Toyokawa G, Matsubara T, Kozuma Y, et al
    Significance of the Preoperative CONUT Score in Predicting Postoperative Disease-free and Overall Survival in Patients with Lung Adenocarcinoma with Obstructive Lung Disease.
    Anticancer Res. 2017;37:2735-2742.
    PubMed     Text format     Abstract available


  171. JINGU K, Matsuo Y, Onishi H, Yamamoto T, et al
    Dose Escalation Improves Outcome in Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Colorectal Cancer.
    Anticancer Res. 2017;37:2709-2713.
    PubMed     Text format     Abstract available


  172. MIYATA T, Oyama T, Yoshimatsu T, Higa H, et al
    The Clinical Significance of Cancer Stem Cell Markers ALDH1A1 and CD133 in Lung Adenocarcinoma.
    Anticancer Res. 2017;37:2541-2547.
    PubMed     Text format     Abstract available


  173. DORE-SAVARD L, Chen Z, Winnard PT Jr, Krishnamachary B, et al
    Delayed Progression of Lung Metastases Following Delivery of a Prodrug-activating Enzyme.
    Anticancer Res. 2017;37:2195-2200.
    PubMed     Text format     Abstract available


    April 2017
  174. TSOUKALAS N, Aravantinou-Fatorou E, Tolia M, Giaginis C, et al
    Epithelial-Mesenchymal Transition in Non Small-cell Lung Cancer.
    Anticancer Res. 2017;37:1773-1778.
    PubMed     Text format     Abstract available


  175. OKAMOTO T, Kohno M, Ito K, Takada K, et al
    Clinical Significance of DNA Damage Response Factors and Chromosomal Instability in Primary Lung Adenocarcinoma.
    Anticancer Res. 2017;37:1729-1735.
    PubMed     Text format     Abstract available


  176. KAITO D, Iihara H, Funaguchi N, Endo J, et al
    Efficacy of Single-dose First-generation 5-HT3 Receptor Antagonist and Dexamethasone for Preventing Nausea and Vomiting Induced by Low-dose Carboplatin-based Chemotherapy.
    Anticancer Res. 2017;37:1965-1970.
    PubMed     Text format     Abstract available


  177. ABE S, Yamashita SI, Miyahara SO, Wakahara J, et al
    Prognostic Significance of BMI-1 But Not MEL-18 Expression in Pulmonary Squamous Cell Carcinoma.
    Anticancer Res. 2017;37:1923-1929.
    PubMed     Text format     Abstract available


    March 2017
  178. KASMANN L, Bolm L, Janssen S, Rades D, et al
    Prognostic Factors and Treatment of Early-stage Small-cell Lung Cancer.
    Anticancer Res. 2017;37:1535-1537.
    PubMed     Text format     Abstract available


  179. YOH K, Goto Y, Naito Y, Kishi K, et al
    Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting.
    Anticancer Res. 2017;37:1507-1513.
    PubMed     Text format     Abstract available


  180. TOYOKAWA G, Takada K, Okamoto T, Kozuma Y, et al
    Elevated Metabolic Activity on 18F-FDG PET/CT Is Associated with the Expression of EZH2 in Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:1393-1401.
    PubMed     Text format     Abstract available


  181. WINDRICHOVA J, Fuchsova R, Kucera R, Topolcan O, et al
    MIC1/GDF15 as a Bone Metastatic Disease Biomarker.
    Anticancer Res. 2017;37:1501-1505.
    PubMed     Text format     Abstract available


  182. TAGAWA T, Ito K, Fukuzawa K, Okamoto T, et al
    Surgical Resection for Pulmonary Metastasis from Pancreatic and Biliary Tract Cancer.
    Anticancer Res. 2017;37:1413-1416.
    PubMed     Text format     Abstract available


  183. BATTOLLA E, Canessa PA, Ferro P, Franceschini MC, et al
    Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.
    Anticancer Res. 2017;37:1387-1391.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: